Presentations

INVITED LECTURES

  1. Balkovec, J. M. “Structure-Activity Relationships of the Echinocandin and Pneumocandin Antifungal Lipopeptides:  Potent Inhibitors of 1,3-b-Glucan Synthesis” presented at New York University, New York, NY:  November 17, 1992.
  2. Balkovec, J. M.; Black, R. M.; Hammond, M. L.; Heck, J. V. and Zambias, R. A.  “Structure-Activity Relationships of the Pneumocandin Antifungal Lipopeptides” presented at American Chemical Society, Medicinal Chemistry Meeting, Denver, CO:  Abstract No. 163, March 28-April 2, 1993.
  3. Balkovec, J. M. “The Fungal Cell Wall as a Drug Discovery Target:  SAR of Novel Echinocandin Analogs” presented at the XIVth International Symposium on Medicinal Chemistry, Maastricht, The Netherlands: September 8-12, 1996.
  4. Balkovec, J. M. “Structure-Activity Relationships of Pneumocandin Antifungal Lipopeptide Agents” presented at New York University, New York, NY:  October 15, 1996.
  5. Balkovec, J. M. “New Developments in Antifungal Agents” presented at the American Chemical Society, Medicinal Chemistry Meeting, San Francisco, CA:  Abstract No. 320, April 13-17, 1997.
  6. Balkovec, J. M. “Natural Born Killers:  Antifungal Antibiotics” presented at the Natural Products Gordon Conference, New England College, Henniker, NH:  July 5-10, 1998.
  7. Balkovec, J. M. “The Development of Lipopeptide Antifungal Agents” presented at Bucknell University, Lewisburg, PA:  March 24, 1999.
  8. Balkovec, J. M. “Natural Born Killers:  Antifungal Antibiotics” presented at the University of Colorado, Boulder, CO:  April 12, 1999.
  9. Balkovec, J. M. “Cell Wall Targets for Antifungal Therapy” presented at the Royal Society of Chemistry 3rd International Symposium on Anti-Infectives, Churchill College, Cambridge UK:  July 23-26, 2000.
  10. Balkovec, J. M. “The Discovery and Development of Cancidas” presented at the MRL Biology/Medicinal Chemistry Course, Princeton, NJ:  March 20, 2001.
  11. Balkovec, J. M.; Black, R. M.; Bouffard, F. A.; Dropinski, J. F.  “Cancidas:  A Novel, Lifesaving Antifungal Agent” presented at the 34th Middle Atlantic Regional Industrial Innovation Awards Ceremony, Towson University, Towson, MD:  June 1, 2001.
  12. Balkovec, J. M. “Novel Antifungal Agents” presented at the Symposium on Frontiers in Biotechnology and Pharmaceuticals, Weihai, China:  August 28-30, 2001.
  13. Balkovec, J. M. “Cancidas: A Novel Lifesaving Antifungal Agent” presented at the Symposium on Frontiers in Biotechnology and Pharmaceuticals, TEDA, Tianjin, China:  September 1, 2001.
  14. Balkovec, J. M. “From Bugs to Drugs: Antifungal Antibiotics” presented at the Columbia University-Merck Medicinal Chemistry Course, New York, NY:  March 25, 2004.
  15. Balkovec, J. M. “11β-Hydroxysteroid Dehydrogenase:  Inhibitors For The Treatment of Metabolic Syndrome” presented at Merck & Co, West Point, PA:  April 29, 2005.
  16. Balkovec, J. M. “From Bugs To Drugs: The Discovery of Caspofungin” presented at ICOB-5 & ISCNP-25 IUPAC International Conference on Biodiversity and Natural Products, Kyoto, Japan:  July 23-28, 2006.
  17. Balkovec, J. M.; Hughes, D.; Schwartz, R. E. “Heroes of Chemistry Lecture:  The Unsung Heroes” presented at Merck & Co., Rahway, NJ:  October 31, 2006.
  18. Balkovec, J. M. “From Bugs To Drugs: The Discovery of Caspofungin” presented at the Society of Industrial Microbiology Annual Meeting in Denver, CO: July 29-Aug 3, 2007.
  19. Balkovec, J. M. “From Bugs To Drugs: Lipopeptide Antifungal Agents” presented at Scynexis, Inc., Research Triangle Park, NC: August 23, 2007.
  20. Balkovec, J. M. “Antifungal Natural Products:  Development of Novel Orally-Active Antifungal Agents” presented at Merck and Co., Boston, MA:  October 17, 2007.
  21. Balkovec, J. M. “11β-Hydroxysteroid Dehydrogenase Inhibitors:  Medication For A Fast Food Nation” presented at The University of Connecticut, Storrs, CT:  April 9, 2008.
  22. Balkovec, J. M. “Natural Products in Drug Discovery: The Development of Cancidas®” presented at the North Jersey American Chemical Society Symposium “Pharmaceutical Success Stories”, Somerset, NJ:  May 22, 2008.
  23. Balkovec, J. M. “Novel Orally Active Antifungal Agents” presented at Merck & Co, Rahway, NJ:  September 29, 2008.
  24. Balkovec, J. M. “11β-HSD1 Inhibitors:  Medication For a Fast Food Nation” presented at Scynexis, Inc., Research Triangle Park, NC: December 5, 2008.
  25. Balkovec, J. M.  “Development of an Orally Active Antifungal Agent Targeting β-1,3-Glucan Synthase” presented at Merck & Co, West Point, PA:  October 28, 2009.
  26. Balkovec, J. M.  “Natural Product β-1,3-Glucan Synthase Inhibitors” presented at the Barry M. Trost 70th Birthday Symposium, Stanford University, Stanford, CA:  June 25, 2011.
  27. Balkovec, J. M.  “Discovery of MK-3118:  An Orally Active Antifungal Agent Targeting β-1,3-Glucan Synthase” presented at the Kenilworth Science Meeting, Merck & Co, Kenilworth, NJ:  July 28, 2011.
  28. Balkovec, J. M. “The Discovery of Cancidas and Beyond” presented at the Joint Meeting of the American Society for Microbiology and Society for Industrial Microbiology & Biotechnology, Rutgers University, New Brunswick, NJ:  March 8, 2012.
  29. Balkovec, J. M.  “Concept to Clinic: Chemical Optimization of Pneumocandin B0 And Selection of The Pre-Clinical Candidate Caspofungin ” presented at the International Congress on Natural Products Research, New York, NY:  July 29–August 2, 2012.
  30. Balkovec, J. M. ”Natural Products in the Quest for Novel Drugs” presented at Fairleigh Dickinson University, Teaneck, NJ:  January 31, 2013.
  31. Balkovec, J.M. and Peel, M. “Drug Discovery Using Natural Products – Optimization Studies of Inhibitors of Glucan Synthesis as Anti-Fungal Agents” presented by XTalks Educational Webinars, http://xtalks.com/Drug-discovery-using-natural-products.ashx, October 31, 2013.
  32. Balkovec, J.M. “Antifungal Therapy:  Discovery of Cancidas® and Future Prospects” presented at the 2015 International (Henan) Forum on Drug Discovery and Technology Transfer, Zhengzhou, Henan Province, PRC:  June 5-7, 2015.
  33. Balkovec, J.M. “Peptide-Derived Natural Products in the Discovery of Anti-Infectives” presented at the 12th Annual Peptide Therapeutics Symposium, La Jolla, CA: October 26-27, 2017.
  34. Balkovec, J.M. “Natural Born Killers: Natural Products in the Discovery of New Drugs” R.I.S.E. Talk Series, presented at Drew University, Madison, NJ: October 24, 2018.
  35. Balkovec, J. M. “Cloudbreak – A Novel Approach to Immunotherapeutics Targeting Infectious Diseases” presented at Oxford Global – Bispecific Discovery and Development Congress, Berlin, Germany: June 11-12, 2019.

PRESENTATIONS AND ABSTRACTS

  1. Balkovec, J. M. “The Total Synthesis of the Iridoid Natural Products Plumericin and Allamandin” presented at Columbia University, New York, NY:  September 17, 1987.
  2. Bartizal, K.; Abruzzo, G.; Trainor, C.; Krupa, D.; Nollstadt, K; Schmatz, D.; Schwartz, R.; Hammond, M.; Balkovec, J.; VanMiddlesworth, F.; “b-1,3-Glucan Synthesis Inhibitors L-671,329, L-646,991, Tetrahydroechinocandin B and a Papulacandin in an Improved Target Organ Kidney Assay (TOKA) of Systemic Candidiasis” presented at 30th ICAAC meeting, Atlanta, GA:  Abstract No. 584, Oct 21-24, 1990.
  3. Balkovec, J.M.; Black, R. M.; Hammond, M. L.; Heck, J. V.; Zambias, R. A.; Abruzzo, G.; Bartizal, K.; Puckett, J.; Trainor, C.; Hajdu, R.; Sundelof, J. G.; Thompson, R.; Schwartz, R.; McFadden, D. C.; Nollstadt, K.; Pittarelli, L. A.; Powles, M. A.; Schmatz, D. M.:  “The Synthesis And Biological Evaluation Of Echinocandin Analogues.  Antifungal And Antipneumocystis Activity Of L-693,989 And Other Water Soluble Analogues Of L-688,786” presented at American Chemical Society Medicinal Chemistry Division 4th Chemical Congress of North America Meeting, New York, NY:  Abstract No. MEDI 182, August 25-30, 1991.
  4. Balkovec, J.M.; Black, R. M.; Hammond, M. L.; Heck, J. V.; Zambias, R. A.; Abruzzo, G.; Bartizal, K.; Puckett, J.; Trainor, C.; Schwartz, R.; McFadden, D. C.; Pittarelli, L. A.; Powles, M. A.; Schmatz, D. M.  “Echinocandin Analogues:  Synthesis and In Vivo Efficacy of L-693,989 and Other Water Soluble Echinocandins In Candida and Pneumocystis Rodent Models” presented at 31st ICAAC meeting, Chicago, IL:  Abstract No. 204, September 29-Oct 2, 1991.
  5. Bartizal, K.; Gill, C.; Renna, C.; Shungu, D.; Abruzzo, G.; Trainor, C.; Puckett, J.; Ponticas, S.; Schwartz, R.; Hammond, M.; Balkovec, J.; Zambias, R.; Kropp, H.  “In Vitro Susceptibility of Clinical Yeast Isolates to an Echinocandin Analog L-688,786 Compared to its Water Soluble Derivative Prodrug L-693,989, Cilofungin and Amphotericin B” presented at 31st ICAAC meeting, Chicago, IL:  Abstract No. 205, September 29-Oct 2, 1991.
  6. Bartizal, K.; Abruzzo, G.; Trainor, C.; Puckett, J.; Ponticas, S.; Krupa, D.; Schmatz, D.; Nollstadt, K.; Schwartz, R.; Hammond, M.; Balkovec, J.; Zambias, R.; Kropp, H.  “Antifungal Activity of L-693,989 a New Water Soluble Prodrug Derivative of an Echinocandin Analog L-688,786” presented at 31st ICAAC meeting, Chicago, IL:  Abstract No. 206, September 29-Oct 2, 1991.
  7. Schmatz, D. M.; Powles, M. A.; McFadden, D. C.; Pittarelli, L.; Balkovec, J.; Zambias, R.; Hammond, M.  “Evaluation of the Antipneumocystis Activity of Water Soluble Lipopeptide L-693,989 in the Rat” presented at 31st ICAAC meeting, Chicago, IL:  Abstract No. 207, September 29-Oct 2, 1991.
  8. Black, R. M.; Balkovec, J. M.; Hammond, M. L.; Abruzzo, G.; Bartizal, K.; Marrinan, J.; Trainor, C.; McFadden, D. C.; Nollstadt, K.; Pittarelli, L.; Powles, M. A.; Schmatz, D. M.  “Selective Reductions of the Echinocandin Ring System.  Investigation of the Antifungal and Antipneumocystis Activity of L-688,786 and Related Analogues” presented at American Chemical Society, Medicinal Chemistry Meeting, San Francisco, CA:  Abstract No. MEDI 63, April 5-10, 1992.
  9. Bouffard, F. A.; Zambias, R. A.; Dropinski, J. F.; Balkovec, J. M.; Hammond, M. L.; Nollstadt, K. H.; Marrinan, J. “Synthesis and Antifungal Activity of Water-Soluble Pneumocandin B0 Derivatives:  L-705589, L-731373 and L-733560” presented at 33rd ICAAC Meeting, New Orleans, LA:  Abstract No. 350, October 17-20, 1993.
  10. Balkovec, J. M.; Black, R. M.; Dreikorn, S.; Nollstadt, K. M. “Pneumocandin Antifungal Lipopeptides:  Substituted Homotyrosine (HTY) Analogs”  presented at the 24th National Medicinal Chemistry Symposium, Salt Lake City, UT:  Abstract No. 57, June 21-24, 1994.
  11. Bouffard, F. A.; Dropinski, J. F.; Balkovec, J. M.; Hammond, M. L.; Nollstadt, K.; McFadden, D.; Powles, M.; Schmatz, D.; Marrinan, J.; Dreikorn, S.; Douglas, C.; Abruzzo, G.; Flattery, A.; Gill, C.; Kong, L.; Lynch, L.; Scott, P.; Smith, J.; Bartizal, K. “Antifungal Lipopeptides:  Synthesis and SAR of Cationic Pneumocandins as Potent Inhibitors of Cell Wall Synthesis” presented at the 28th ACS Great Lakes Regional Meeting, LaCrosse, WI:  Abstract No. MEDI 110, June 6-8, 1995.
  12. Balkovec, J. M.; Zambias, R. A.; James, C. A.; Nollstadt, K. H.; Douglas, C. M.; Marrinan, J. A.; Abruzzo, G. K. and Bartizal, K. F. “Antifungal Lipopeptides:  SAR Of Novel Amino Acid Conjugates Of Pneumocandin B0 Analogs L-731,373 and L-733,560” presented at the National ACS Meeting, Chicago, IL:  Abstract No. MEDI 213, August 23-28, 1995.
  13. Dropinski, J. F.; Bouffard, F. A.; Balkovec, J. M.; Hammond, M. L.; Adefarati, A. A.; Nollstadt, K. H.; Marrinan, J. A.; Dreikorn, S. and Abruzzo, G. K. “Synthesis and SAR of Pneumocandin B0 Side Chain Variants” presented at the National ACS Meeting, New Orleans, LA:  Abstract No. MEDI 196, March 24-29, 1996.
  14. Black, R. M.; Balkovec, J. M.; Hammond, M. L.; Nollstadt, K. H.; Marrinan, J. A.; Dreikorn, S. and Abruzzo, G. K. “Antifungal Lipopeptides:  Amine Substitution at the C5-Orn and C4-Hty Positions of Pneumocandin B0 and Its Biological Effect” presented at the National ACS Meeting, Orlando, FL:  Abstract No. MEDI 32, August 25-29, 1996.
  15. Bouffard, F. A.; Dropinski, J. F.; Balkovec, J. M.; Black, R. M.; Hammond, M. L.; Nollstadt, K. H.; Dreikorn, S. “L-743,872, a Novel Antifungal Lipopeptide:  Synthesis and Structure-Activity Relationships of New Aza-Substituted Pneumocandins” presented at the 36th ICAAC Meeting, New Orleans, LA:  Abstract No. F27, September 15-18, 1996.
  16. Tse, B.; Blazey, C. M.; Tu, B.; Balkovec, J. “Determination of the absolute stereochemistry of (-)-galbonolide A” presented at the 214th National ACS Meeting, Las Vegas, NV:  Abstract No. ORG 271, September 7-11, 1997.
  17. Dropinski, J. F.; Bouffard, F. A.; Balkovec, J. Adefarati, A.; Dreikorn, S.; Nollstadt, K.; Powles, M. A.; Hajdu, R.; Abruzzo, G.; Flattery, A.; Gill, C.; Kong, L.; Bartizal, K. “Side Chain-Modified Pneumocandins:  Derivatives of L-733,560” presented at the 214th National Medicinal Chemistry Meeting, VA:  Abstract No. B-1, June 14-18, 1998.
  18. Tse, B.; Balkovec, J.; Blazey, C. M.; Hsu, M.-J.; Nielsen, J.; Schmatz, D. “Alkyl Side-Chain Derivatives of Sordaricin as Potent Antifungal Agents Against Yeast” presented at the XVth EFMC International Symposium on Medicinal Chemistry, Edinburgh, Scotland:  Abstract No. 165, September 6-10, 1998.
  19. Epstein-Toney, J. H.; Fitzgerald, P. M. D.; Sharma, N.; Greenlee, M. L.; Leiting, B.; Pryor, K. A.; Wu, J. K.; Huber, J. L.; Laub, J. B.; Young, K. Silver, L. L.; Vanderwall, D. E.; Balkovec, J. M.; Hammond, M. L.; Heck, J. V.; Kozarich, J. W.; Pompliano, D. L.; Hammond, G. G. “Antibiotic Sensitization:  Design of metallo-b-lactamase inhibitors” presented at the International Congress on Beta-lactamases, Rome, Italy, June 17-20, 1999.
  20. Olson, S.; Balkovec, J.; Brown, K.; Carbin, L.; Gao, Y.-D.; Hermanowski-Vosatka, A.; LeGrand, C.; Mundt, S.; Robbins, M.; Slossberg, L.; Szymonifka, M.; Thieringer, R. “Selective Inhibitors of 11b-Hydroxysteroid Dehydrogenase Type 1 as Novel Therapeutic Agents for the Treatment of Metabolic Syndrome” presented at the Natural Products Research Gordon Conference, Tilton School, Tilton, NH, July 27-August 1, 2003.
  21. Olson, S.; Balkovec, J.; Gao, Y.-D.; Robbins, M.; Slossberg, L.; Szymonifka, M.; Hermanowski-Vosatka, A.; Mundt, S.; Thieringer, R.; Wright S. “Selective Inhibitors of 11b-Hydroxysteroid Dehydrogenase Type 1.  Adamantyl Triazoles as Pharmacological Agents for the Treatment of Metabolic Syndrome” presented at: Keystone Symposium: Molecular Control of Adipogenesis and Obesity Meeting, Banff, Canada, March 4-10, 2004.
  22. Hermanowski-Vosatka, A.; Mundt, S.; Nunes, C.; Strowski, M.; Li, Z.; Zhang, B.; Frazier, E.; Le Grand, C.; Chen, H.; Robertson, N.; Metzger, J.; Strack, A., Olson, S.; Schaeffer, J.; Wright; S.D.; Balkovec, J.; Thieringer, R. “11b-HSD1 Inhibition Ameliorates Metabolic Syndrome in Mice” presented at: Keystone Symposium: Molecular Control of Adipogenesis and Obesity Meeting, Banff, Canada, March 4-10, 2004.
  23. Thieringer, R.; Balkovec, J. M.; Chen, H.; Frazier, E.; Le Grand, C. B.; Liu, Z.; Metzger, J. M.; Mundt, S. S.; Nunes, C.; Olson, S. H.; Robertson, N.; Strack, A. M.; Strowski, M.; Schaeffer, J. M.; Wright, S. D.; Zhang, B. B.; Hermanowski-Vosatka, A. “A Novel Non-Steroidal Inhibitor of 11β-Hydroxysteroid Dehydrogenase Type 1 Improves Features of Metabolic Syndrome in Murine Disease Models” presented at:  The British Endocrine Society Meeting, Brighton, UK, March 22-24, 2004.
  24. Ali, A.; Thompson, C.F.; Balkovec, J.; Graham, D.W.; Hammond, M.L.; Quraishi, N.; Tata, J.R.; Einstein, M.; GE, L.; Harris, G.; Kely, T.M.; Mazur, P.; Pandit, S.; Santoro, J.; Sitlani, A.; Wang, C.; Williamson, J.M.; Miller, D.K.; Thompson, C.M.; Zaller, D.M.; Forrest, M.J.; Carballo-Jane, E.; Luell, S. “Discovery of Novel, Non-Steroidal Glucocorticoid Receptor Modulators” presented at: The Tenth Conference of the French-American Chemical Society, Charleston, SC, June 6, 2004.
  25. Hermanowski-Vosatka, A.; Mundt, S.; Nunes, C.; Strowski, M.; Li, Z.; Zhang, B.; Le Grand, C.; Chen, H.; Robertson, N.; Metzger, J.; Strack, A., Olson, S.; Springer, M.; Balkovec, J.; Wright; S.D.; Thieringer, R. “11β-HSD1 Inhibition Ameliorates Metabolic Syndrome in Mice”presented at: Drugs Affecting Lipid Metabolism 15th Annual Meeting (DALM), Venice, Italy, October 24-27, 2004.
  26. Rosko, K.M., Bradbury, M. J.; Balkovec, J. M.; Gagen, K.; Olson, S. H.; Gorski, J. N.; Yang, L.; Robertson, N.; Chapman, D. F.; Dogariu, A. C.; Thieringer, R.; Hermanowski-Vosatka, A., Strack, A. M.; Metzger, J. M. “Pharmacologic Inhibition Of 11β-HSD1 Improves Measures of Metabolic Syndrome Without Impairment of HPA Function In DIO Mice” presented at: Federation Of American Societies For Experimental Biology Meeting (FASEB), San Diego, CA, April 2-6, 2005.
  27. Hermanowski-Vosatka, A., Balkovec, J. M.; Cheng, K.; Chen, H. Y.; Hernandez, M.; Koo, G. C.; Le Grand, C. B.; Li, Z.; Metzger, J. M.; Mundt, S. S.; Noonan, H.; Nunes, C. N.; Olson, S. H.; Pikounis, V. B.; Ren, N.; Robertson, N.; Schaeffer, J. M.; Shah, K.; Springer, M. S.; Strack, A. M.; Strowski, M. Z.; Wu, K. K.; Wu, T.: Xiao, J.; Zhang, B. B.; Wright, S. D.; Thieringer, R. “11β-HSD1 Inhibition Ameliorates Metabolic Syndrome and Prevents Progression of Atherosclerosis in Mice” presented at: Prediabetes And Metabolic Syndrome 1st Congress, Berlin, Germany, April 12-16, 2005
  28. Olson, S.H. ; Balkovec, J. M.; Gao, Y.; Zhu, Y.; Ding, G. J. F.; Hermanowski-Vosatka, A.; Koo, G. C.; Koprak, S. L.; Mundt, S. S.; Shah, K.; Springer, M. S.; Thieringer, R.; Wright, S. D.; Xiao, J.; Zokian, H. J. “Benzyl Triazole Inhibitors of 11β-Hydroxysteroid Dehydrogenase Type 1. Pharmacological Agents For The Treatment of Metabolic Syndrome” presented at: Gordon Research Conference On Natural Products, Tilton, NH, July 24-29, 2005.
  29. Waddell, S.T. ; Gu, X.; Santorelli, G.M.; Balkovec, J.M.; Graham, D.W. “Bicyclo[2.2.2]octyltriazole Inhibitors of 11beta-HSD1” presented at: American Chemical Society 231st National Meeting, Atlanta, GA, March 26-30, 2006.
  30. Maletic, M.M.; Leeman, A.H.; Mundt, S.S.; Zokian, H.J.; Dragovic, J., Lyons, K.A.; Koprak, S.L.; Koo, G.C.; Cheng, K.; Tan, E.Y.; Shah, K.; Thieringer, R.; Hermanowski-Vosatka, A.; Springer, M.S.; Balkovec, J.M.; Waddell, S.T.  “Bicyclo[2.2.2]octyltriazole Inhibitors of 11beta-Hydroxysteroid Dehydrogenase Type 1. Pharmacological Agents For the Treatment of Metabolic Syndrome” presented at: American Chemical Society 231st National Meeting, Atlanta, GA, March 26-30, 2006.
  31. Ali, A.; Thompson, C.F.; Balkovec, J.; Graham, D.; Greenlee, M.; Hammond, M.L.; Quraishi1, N.; Rouen, G.; Smith, C.; Tata, J.R.; Taylor, G.; Einstein, M.; Ge, L.; Harris, G.; Kelly, T.M.; Mazur, P.; Pandit, S.; Santoro, J.; Sitlani, A.; Wang, C; Williamson, J.; Miller, D.F.; O’Neill, E.A.; Thompson, C.M.; Zaller, D.M.; Forrest, M.J.; Carballo-Jane, E.; Luell, S.; Visco, D.; Rasa, C.; Lowitz, K. “Discovery of Novel, Selective Glucocorticoid Receptor Modulators” presented at: American Chemical Society 233rd National Meeting, Chicago, IL, March 25-29, 2007.
  32. Waddell, S.T.;  Maletic, M.; Santorelli, G.; Leeman, A.; Graham, D.; Balkovec, J.M.  “Bicyclo[2.2.2]octyl-triazole Inhibitors of 11beta-HSD1 are Efficacious in Animal Models of Metabolic Disease”  presented at: American Chemical Society 233rd National Meeting, Chicago, IL, March 25-29, 2007.
  33. Gao, Y.; Olson, S.H.; Balkovec, J.; Zhu, Y.; Royo, I.; Yabut, J.; Evers, R.; Tan, E.Y.; Tang, W.; Hartley, D.P.; Mosley, R.T.  “ADME Modeling Using Structural Data: Structure Guided Elimination of PXR Activity” presented at: American Chemical Society 232nd National Meeting, Chicago, IL, March 25-29, 2007.
  34. Maletic, M.M.; Leeman, A.H.; Szymonifka, M.J., Mundt, S.S.; Zokian, H.J.; Shah, K., Dragovic, J., Tan, E.Y., Koprak, S.L.; Koo, G.C.; Chang, R., Thieringer, R., Metzger, J.M., Hermanowski-Vosatka, A.; Balkovec, J.M.; Waddell, S.T. “Bicyclo[2.2.2]octyltriazole inhibitors of 11β-hydoxysteroid dehydrogenase type 1. Pharmacological agents for the treatment of metabolic syndrome” presented at: Keystone Symposia: Metabolic Syndrome And Cardiovascular Risk Conference, Steamboat Springs, CO, March 27-April 1, 2007.
  35. Zhu, Y. , Olson, S.H., Graham, D.W., Patel, G.F., Hermanowski-Vosatka, A., Mundt, S.S., Shah, K., Springer, M.S., Thieringer, R., Wright, S.D., Xiao, J., Zokian, H.J., Dragovic, J., Balkovec, J.M. “Phenylcylcobutyl triazoles as selective inhibitors of 11β-hydroxysteroid dehydrogenase type I” presented at the American Chemical Society 236th National Meeting And Exposition, Philadelphia, Pennsylvania, August 17-21, 2008.
  36. Balkovec, J. M.; Bouffard, F.A., Dropinski, J.F., Shi, G.; Siliphaivanh, P., Abruzzo, G.K., Flattery, A.M., Gill, C.J., Kong, L., Leighton, C.C., Nielsen-Kahn, J.N., Hsu, M., Onishi, J.C., Pivnichny, J.V., Tong, X.S.; Wilson, K.E.  “Structure-Activity Relationships of the β-1,3-Glucan Synthase Inhibitor Enfumafungin” poster presented at the Natural Products Gordon Conference, Tilton School, Tilton, NH:  July 26-31, 2009.
  37. Maletic, M.; Leeman, A.; Waddell, S.T.; Balkovec, J.M..   “Medication For The Fast Food Nation: Bicyclo[2.2.2]octyltriazole Inhibitors of 11β-HSD1 For The Treatment of Metabolic Syndrome”   presented at the 238th ACS National Meeting, Washington, DC: August 16-20, 2009
  38. Balkovec, J. M.; Bouffard, F.A., Dropinski, J.F., Shi, G.; Siliphaivanh, P., Abruzzo, G.K., Flattery, A.M., Gill, C.J., Kong, L., Leighton, C.C., Nielsen-Kahn, J.N., Hsu, M., Onishi, J.C., Pivnichny, J.V., Tong, X.S.; Wilson, K.E.   “Derivatives of the β-1,3-Glucan Synthase (GS) Inhibitor Enfumafungin – Initial Studies” presented at Interscience Conference On Antimicrobial Agents And Chemotherapy 49th Annual Meeting (ICAAC), San Francisco, California:  September 12-15, 2009.
  39. Liberator, P.A. , Giacobbe, R.A., Racine, F., Motyl, M.R., Hsu, M., Nielsen-Kahn, J., Bowman, J.C., Douglas, C.M., Hammond, M.L., Balkovec, J.M., Greenlee, M.L., Meng, D., Parker, D.L., Peel, M., Fan, W., Mamai, A., Hong, J., Orr, M., Ouvry, G., Perry, D., Liu, H., Jones, M., Nelson, K., Ogbu, C., Lee, S., LI, K., Kirwan, R., Noe, A., Sligar, J., Martensen, P. “Semi-Synthetic Analogs of Enfumafungin: Novel Inhibitors of beta-1,3-Glucan Synthase (GS) With Potent In Vitro Anti-Fungal Activity” presented at Interscience Conference On Antimicrobial Agents And Chemotherapy 49th Annual Meeting (ICAAC), San Francisco, California:  September 12-15, 2009.
  40. Peel, M., Mamai, A., Fan, W., Dimick-Gray, S., Hong, J., Orr, M., Balkovec, J.M.* , Greenlee, M.L., Waddell, S.T., Abruzzo, G.K., Flattery, A.M., Giacobbe, R.A., Gill, C.J., Hsu, M., Racine, F., Liberator, P.A., Nielsen-Kahn, J. “New beta-1,3-Glucan Synthase (GS) Inhibitors With Potent Antifungal Activity” presented at Interscience Conference On Antimicrobial Agents And Chemotherapy 49th Annual Meeting (ICAAC), San Francisco, California:  September 12-15, 2009.
  41. Peel, M., Mamai, A., Fan, W., Dimick-Gray, S., Hong, J., Orr, Ouvry, G.; Perrey, D.; Liu, H.; Jones, M.; Nelson, K.; Ogbu, C.; Lee, S.; Li, K.; Kirwan, R.; Noe, A.; Sligar, A.; Martensen, P.; Balkovec, J.; Greenlee, M.; Waddell, S.T., Abruzzo, G.K., Flattery, A.M., Giacobbe, R.A., Gill, C.J., Hsu, M., Racine, F., Liberator, P.A., Nielsen-Kahn, J. “New beta-1,3-Glucan Synthase (GS) Inhibitors With Potent Antifungal Activity” to be presented at the 9th International Mycological Congress (IMC9), Edinburgh, UK August 1-6, 2010.
  42. Wilkening, R.; Apgar, J.; Meng, D.; Parker, D.; Greenlee, M.; Sperbeck, D.; Wildonger, K.; Abruzzo, G.;  Flattery, A.; Galgoci, A.; Giacobbe, R.; Gill, C.;  Hsu, M.; Liberator, P.; Misura, A.; Motyl, M.; Nielsen-Kahn, J.; Powles, M. A.; Racine, F.; Dragovic, J.; Habulihaz, B.; Fabre, E.; Fan, W.; Heasley, B.; Kirwan, R.; Lee, S.; Liu, H.; Mamai, A.; Nelson, K.; Pacofsky, G.; Peel, M.; Balkovec, J. M.  “Enfumafungin Derivatives:  Orally-Active Glucan Synthase Inhibitors” presented at Interscience Conference On Antimicrobial Agents And Chemotherapy 50th Annual Meeting (ICAAC), Boston, Massachusetts:  September 12-15, 2010.
  43. Peel, M.; Fan, W.; Mamai, A.; Hong, J.; Orr, M.; Ouvry, G.; Perrey, D.; Liu, H.; Jones, M.; Nelson, K.; Ogbu, C.; Lee, S.; Li, K.; Kirwan, R.; Noe, A.; Sligar, A.; Martensen, P.; Balkovec, J.; Greenlee, M. ; Meng, D.;  Parker, D.; Wildonger, K.; Abruzzo, G.;  Flattery, A.; Galgoci, A.; Giacobbe, R.; Gill, C.;  Hsu, M.; Liberator, P.; Misura, A.; Nielsen-Kahn, J.; Powles, M. A.; Racine, F.; Dragovic, J.; Habulihaz, B.; Balkovec, J.  “Enfumafungin Derivatives:  Orally-Active Glucan Synthase Inhibitors” presented at Interscience Conference On Antimicrobial Agents And Chemotherapy 50th Annual Meeting (ICAAC), Boston, Massachusetts:  September 12-15, 2010.
  44. Motyl, M.; Tan, C.; Liberator, P.; Giacobbe, R.;  Racine, F.; Hsu, M. J.; Nielsen-Kahn, J.; Bowman, J.; Douglas, C.; Hammond, M.;Balkovec, J. M.; Greenlee, M. L.; Meng, D.; Parker, D.; Peel, M.; Fan, W.; Mamai, A.; Hong, J.; Orr, M.; Ouvry, G.; Perrey, D.; Liu, H.; Jones, M.; Nelson, K.; Ogbu, C.; Lee, S.; Li, K.; Kirwan, R.; Noe, A.; Sligar, A.; Martensen, P. “MK-3118, An Oral Enfumafungin With Potent In Vitro Activity Against Candida and Aspergillus spp.” presented at Interscience Conference On Antimicrobial Agents And Chemotherapy 50th Annual Meeting (ICAAC), Boston, Massachusetts:  September 12-15, 2010.
  45. Yoshimoto, R.; Pinto, S. , Balkovec, J.M., Carballo-Jane, E., Chen, S., Chen, D., DeVita, R.J., Forrest, G., Gold, S.J., Guan, X., Gorski, J.N., Hubert, J.A., Leavitt, P.S., Metzger, J.M., Misura, A.S., Nawrocki, A.R., Shen, Z., Szeto, D.M., Xiao, J., Marsh, D.J., Yoshimoto, R. “Pharmacological inhibition of diacylglycerol acyltransferase 1 leads to weight loss and prolongation of glp-1 release” presented at Keystone Symposia: Type 2 Diabetes, Insulin Resistance And Metabolic Dysfunction And Obesity Joint Meeting, Keystone, Colorado, January 12-17, 2011.
  46. Cernak, T.A. , Dykstra, K.D., Verras, A., LeVorse, D.A., Balkovec, J.M., Nargund, R.P., DeVita, R.J. “Synthesis of oxaspiropiperidines as a strategy for lowering logD” presented at the Gordon Research Conference: Heterocyclic Compounds Conference, Newport, Rhode Island, June 26 – July 1, 2011.
  47. Li, W. ; Joshi, A., Zeng, Z.; O’Malley, S.S.; Miller, P.A.; Riffel, K.A., Purcell; M.L., Gantert, L.T., Eng, W., Krause, S.M., Williams, M., Balkovec, J.M., Waddell, S.T., Cook, J.J., Hamill, T.G. “Radiosynthesis and evaluation of an 11-beta hydroxysteroid dehydrogenase-1 (11beta-HSD1) pet ligand in rhesus monkey”  presented at: International 19th Symposium On Radiopharmaceutical Sciences, Amsterdam, the Netherlands, August 28 – September 2, 2011.
  48. Peel, M.; Fan, W.; Pacofsky, G.; Mamai, A.; Hong, J.; Ouvry, G.; Balkovec, J.; Abruzzo, G.; Flattery, A.; Giacobbe, R.; Gill, C.; Hsu, M.-J.; Racine, F.; Liberator, P.; Nielsen-Kahn J. “Semisynthetic b-1,3-glucan synthase (GS) inhibitors with potent antifungal activity” presented at: American Chemical Society National Spring 243rd Meeting And Exposition, San Diego, California, March 25 – 29, 2012.
  49. Peel, M.; Pacofsky, G.; Fan, W.; Mamai, A.; Nelson, K.; Balkovec, J.; Flattery, A.; Giacobbe, R.; Nielsen-Kahn J.; Liberator, P. “Antifungal activity of semisynthetic b-1,3-glucan synthase (GS) inhibitors” presented at: American Chemical Society National Spring 243rd Meeting And Exposition, San Diego, California, March 25 – 29, 2012.
  50. Apgar, J.M. ; Wilkening, R.R.; Meng, D.; Parker, D.L.; Greenlee, M.L.; Sperbeck, D.M.; Wildonger, K.J.; Abruzzo, G.K.; Flattery, A.M.; Galgoci, A.M.; Giacobbe, R.A.; Gill, C.J.; Hsu, M.; Liberator, P.A.; Misura, A.S.; Motyl, M.R.; Kahn, J.N.; Powles, M.A.; Racine, F.; Cormarkovic-Dragovic, J.; Habulihaz, B.; Fabre, E.; Fan, W.; Heasley, B.; Kirwan, R.; Lee, S.; Liu, H.; Mamai, A.; Nelson, K.; Pacofsky, G.; Peel, M.; Balkovec, J.M. “Novel enfumafungin derivatives: orally active beta-1,3-glucan synthesis inhibitors”  presented at American Chemical Society National Fall 244th Meeting And Exposition, Philadelphia, Pennsylvania, August 19– 23, 2012.
  51. Ong, V.; Hough, G.; Schlosser, M.; Bartizal, K.; Balkovec, J.; James, K.; Krishnan, R. “Preclinical Evaluation Shows CD101, a Novel Echinocandin, is Highly Stable with No Hepatotoxicity in Rats” presented at Interscience Conference on Antimicrobial Agents And Chemotherapy 55th Annual Meeting (ICAAC), San Diego, California:  September 17-21, 2015.
  52. Irimia, D.; Jones, C.;  Forrest, K. M.;  Judice, J. K.;  Locke, J. B.; Almaguer, A.; Balkovec, J. M. “Bifunctional Small Molecule Immunotherapy.  C-001 and C-016 Attract Neutrophils (PMNs) to Inhibit Aspergillus fumigatus (Af) Growth in Microfluidic Chambers” presented at Interscience Conference on Antimicrobial Agents and Chemotherapy 55th Annual Meeting (ICAAC), San Diego, California:  September 17-21, 2015.
  53. Jones, C.;  Forrest, K. M.;  Judice, J. K.;  Locke, J. B.; Almaguer, A.; Irimia, D.; Balkovec, J. M. “Bifunctional Small Molecule Immunotherapy.  C-001 and C-016 Attract Neutrophils (PMNs) to Inhibit Aspergillus fumigatus (Af) Growth in Microfluidic Chambers” presented at TROSTCON 75, Stanford University, Stanford, CA:  May 21, 2016.
  54. La Chat, C.; Almaguer, A.; Donatelli, J.; Borchardt, A.; Balkovec, J.; Bartizal, K.; Locke; J. “Antibacterial activity of CD201, a novel lipopolysaccharide-binding antibacterial immunotherapy, against recent Gram-negative clinical isolates, including colistin-resistant strains” presented at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna, Austria: April 22-25, 2017.
  55. La Chat, C.; Almaguer, A.; Donatelli, J.; Borchardt, A.; Balkovec, J.; Bartizal, K.; Locke; J. “In vitro characterization of antibacterial activity, cidality and spontaneous resistance potential of CD201, a novel lipopolysaccharide-binding antibacterial immunotherapy” presented at 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Vienna, Austria: April 22-25, 2017.
  56. Do, Q.-Q.; Noncovich, A.; Brady, T.; Borchardt, A.; Locke, J.; Almaguer, A.; La Chat, C.; Donatelli, J.; Luckashenak, N.; Abelovski, E.; Amundson, K.; Balkovec, J.; Bartizal, K.; Tari, L.; Ong, V.; Levin, J. “Characterization of novel cyclic polypeptides with potent in vitro and in vivo activity against multidrug-resistant Gram-negative pathogens, and reduced nephrotoxicity relative to colistin” presented at the ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, Lisbon, Portugal: September 4-7, 2018.
  57. Tari, L. W.; Borchardt, A.; Lam, T.; Chen, Z.; Bensen, D. C.; Martin-Sancho, L.; Chanda, S.; Akers-Rodriguez, S.; Fortier, J.; Levin, J.; Abelovski, E.; Cole, J.; Doehrmann, S.; Ong, V.; Bartizal, K.; Balkovec, J. M. “Cloudbreak – A novel approach for treatment and prevention of influenza” presented at 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Amsterdam, Netherlands: April 13-16, 2019.
  58. Borchardt, A.; Lam, T.; Chen, Z.; Jiang, W.; Bensen, D. C.; Martin-Sancho, L.; Chanda, S. K.; Akers-Rodriguez, S.; Fortier, J.; Levin, J.; Amundson, K.; Abelovski, E.; Grewal, R.; Cole, J.; Doehrmann, S.; Ong, V.; Bartizal, K.; Balkovec, J. M.; Tari, L. W. “CB-012 – A novel antiviral-Fc conjugate for treatment and prevention of influenza”presented at ASM Microbe, San Francisco, California:  June 20-24, 2019.
  59. Levin, J.; Borchardt, A.; Lam, T.; Jiang, W.; Chen, Z.; Do, Q.-Q.;  Brady, T.; Noncovich, A.; Fortier, J.; Akers-Rodriguez, S.; Bensen, D.; Chenine, A.; Amundson, K.; Locke, J.; Donatelli, J.; La Chat, C.; Almaguer, A.; Hough, G.; Cole, J.; Doehrmann, S.; Grewal, R.; Abelovski, E.; Balkovec, J.; Bartizal, K.; Ong, V.; Tari, L. “Superior Therapeutic Efficacy of CB-012, a Novel Cloudbreak Fc Conjugate in a Lethal Mouse Model of Influenza A (H1N1) and With Activity Against H3N2 and OseltamivirR Isolates” to be presented at Options X for the Control of Influenza, SUNTEC Singapore: August 28-September 1, 2019.
  60. Ong, V.; Levin, J.; Borchardt, A.; Lam, T.; Jiang, W.; Chen, Z.; Do, Q.-Q.;  Brady, T.; Noncovich, A.; Fortier, J.; Akers-Rodriguez, S.; Bensen, D.; Chenine, A.; Amundson, K.; Locke, J.; Donatelli, J.; La Chat, C.; Almaguer, A.; Hough, G.; Cole, J.; Doehrmann, S.; Grewal, R.; Abelovski, E.; Balkovec, J.; Bartizal, K.; Tari, L. “Preclinical Efficacy, Pharmacokinetics, and Safety of CB-012, a Novel Antiviral Fc-Conjugate Against Influenza” presented at Options X for the Control of Influenza, SUNTEC Singapore: August 28-September 1, 2019.
  61. Ong, V.; Levin, J.; Borchardt, Brady, T.; A.; Lam, Noncovich, A.; Fortier, J.; Amundson, K.; Locke, J.; Almaguer, A.; Dedeic, N.; Hough, G.; Cole, J.; Doehrmann, S.; Grewal, R.; Abelovski, E.; Balkovec, J.; Schlosser. M.; Bartizal, K.; Tari, L. “New Generation Antiviral Conjugate (AVC): Stable, Safe, and Single” presented at ID Week 2020, (online): October 21-25, 2020.
  62. Lovey, A.; Krel, M.; Wang, M.; Borchardt, A.; Brady, T.; Cole, J. N.; Do, Q-Q.; Fortier, J.; Hough, G.; Jiang, W.; Noncovich, A.; Tari, L.; Zhao, Q.; Balkovec, J. M.; Zhao, Y.; Perlin, D. S. “Development Of Drug-Fc Conjugates As Immunoprophylactic Agents Against Multidrug Resistant Gram-negative Bacterial Infections” presented at ASM Microbe, Houston, Texas:  June 9-13, 2022.